Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
This was an open label, multi-center protocol for U.S. patients enrolled in the study of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, high risk early breast cancer
Epistemonikos ID: 186b905ec55846a6857bbaf8334daa8e353a7ded
First added on: May 20, 2024